Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS2300 + almonertinib
- Development stage
- Discontinued
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**HRS2300 + almonertinib** is an investigational combination therapy composed of two small molecule drugs: HRS2300 and almonertinib. HRS2300 is an experimental chemical drug developed by Jiangsu Hengrui Pharmaceuticals, whose specific molecular target and mechanism of action have not been publicly disclosed as of September 2025. Almonertinib (HS-10296) is a third-generation, orally available EGFR tyrosine kinase inhibitor that selectively inhibits both EGFR sensitizing and T790M resistance mutations, used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. The combination has been studied in Phase 1 clinical trials for the treatment of advanced malignancies, including advanced cancer and malignant solid neoplasms, but development for this combination appears to have been discontinued after Phase 1[1][3][5][7].
- Other names
- HRS-2300HRS2300HRS 2300HS-10296HS10296HS 10296
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)EGFR exon 19del (Epidermal growth factor receptor exon 19 deletion mutant)EGFR L858R (Epidermal growth factor receptor L858R mutant)
Beyond the preview
Go deeper on HRS2300 + almonertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS2300 + almonertinib.